摘要
狼疮性肾炎(LN)是系统性红斑狼疮(SLE)最常见的严重并发症之一,免疫抑制治疗在其管理中起着关键作用。近年来,靶向生物制剂以其治疗精准、不良反应较少的独特优点在临床广泛应用。本文对近年来几种主要的靶向生物制剂,包括贝利尤单抗、泰它西普、利妥昔单抗等的作用机制、疗效及安全性评价进行综述。
Lupus nephritis is one of the most common and severe complications of systemic lupus erythematosus,and immunosuppressive therapy is crucial in its management.In recent years,targeted biologics have been widely applied in clinical practice due to their unique advantages in precise treatment and fewer adverse reactions.This article reviews the mechanisms,efficacy,and safety evaluations of several major targeted biologics that have emerged in recent years,including belimumab,etanercept,and rituximab.
作者
兰天
骆任娜
杨宁
LAN Tian;LUO Renna;YANG Ning(Department of Nephrology,the First Affiliated Hospital of Dalian Medical University,Dalian 116011,China;Graduate School,Dalian Medical University,Dalian 116044,China)
出处
《大连医科大学学报》
2024年第5期456-460,共5页
Journal of Dalian Medical University
关键词
狼疮肾炎
免疫抑制
靶向治疗
lupus nephritis
immunosuppressive agents
targeted therapy
作者简介
第一作者:兰天(1999-),女,硕士研究生。E-mail:AdaKIDNEY@163.com;通信作者:杨宁,主任医师。E-mail:kidney2003@126.com。
